| |
Expanded Access Program Opens Sept 11 for Merck Integrase Inhibitor Drug MK-0518 in the U.S.A. with toll free tel. number and website to register
|
| |
| |
This Monday, September 11, the Expanded Access program for MK-0518, also known as EARMRK, will officially open in the U.S. The program is intended to provide MK-0158, Merck's investigational integrase inhibitor, to patients who need it most: those with resistance to at least one drug in all three classes of oral anti-HIV medications who are failing their current regimen and require a medication to which they may not be resistant as part of their regimen. Like most expanded access programs, Merck will provide MK-0518 free to patients who qualify, and these patients will be monitored per a research protocol and have their AEs reported by their physician. Further details about the program may be found in the attached information sheet (first attachment).
Please note that Merck is not currently planning to issue a press release on the subject, since a global release was already issue in conjunction with the International AIDS Conference in Toronto last month.
Merck set up a toll-free number (1-877-EARMRK1) and a website (www.earmrk.com, which is part of our existing clinical trial site www.benchmrk.com), through which physicians can contact Parexel, the contract research organization responsible for conducting the Expanded Access program.
Download the Merck EARMRK PDF Here
|
|
| |
| |
|
|
|
